Product INN: Amantadini hydrochloridum

Deva: 100 mg hard capsules

Product ATC Code: N04BB01

Product Description

This medicine contains amantadine hydrochloride, which belongs to a group of medicines called dopaminergic agents. This medicine reduces muscle stiffness, limitation of motion and movement slowness. Neomidantan® also is an antiviral agent.

Product Therapeutic Indications

Neomidantan® is used
- to treat Parkinson's disease, secondary Parkinsonism (characterized by tremor, rigidity or postural instability), including drug-induced extrapyramidal reactions;
- to treat or prevent a certain type of flu infection (influenza A) in adults and children above 10 years of age;
- to treat postherpetic neuralgia (painful condition affecting your nerve fibers and skin)


It is recommended to take Neomidantan® after meals, swallowed whole with a sufficient amount of fluid.

Parkinson's disease, secondary Parkinsonism:
Initially 100mg daily is recommended; after the first week increasing the dose to 100 mg twice daily. The maximum daily dose is 400 mg.
An enhanced therapeutic effect is achieved when the therapy is initiated at an early stage of the disease. Doses exceeding 200mg daily may provide some additional relief, but may also be associated with increased toxicity. The therapeutic effect is observed within a few days. Neomidantan® may appear to lose efficacy within a few months of continuous treatment in some patients. Its effectiveness may be prolonged by withdrawal for three to four weeks, which seems to restore activity. During this time, existing concomitant antiparkinsonian therapy should be continued, or a low dose levodopa treatment initiated.
Neomidantan® should not be stopped abruptly. Neomidantan® withdrawal should be gradual, e.g. half the dose at weekly intervals.
The desired therapeutic effect of antiparkinson agents is achieved gradually. Treatment is symptomatic; the therapeutic effect is observed during and shortly after using Neomidantan®.
Combined treatment: any antiparkinson medicine already in use should be continued during initial Neomidantan® treatment. It may then be possible to reduce the dose of other medicines gradually. In case of increased side effect occurrence, the dosage should be reduced more quickly. In patients receiving large doses of anticholinergic agents or levodopa, the initial phase of Neomidantan® treatment should be extended to 2 weeks.

Treatment of influenza:
It is recommended to start treating influenza as early as possible, advisably within 24 - 48 hours of symptoms appearing.
Adults and children above 10 years of age: 100 mg 1-2 times per day for 5 days.

Prophylaxis of influenza:
Adults and children above 10 years of age: 100 mg daily for up to 6 weeks. When used with inactivated influenza A vaccine, amantadine is continued for 2 to 3 weeks following inoculation.

Postherpetic neuralgia:
Treatment should be started as soon as possible after the diagnosis. The recommended dose is 100 mg twice daily for 14 days. If necessary, treatment can be continued for a further 14 days.

Elderly (over 65 years of age):
The recommended dose is 100 mg a day. Elderly patients are at risk of kidney impairment, as a result amantadine elimination half-life is prolonged and renal clearance of the compound is diminished, therefore, toxicity risk increases. A daily dose of 100 mg a day given at intervals of greater than one day, may be appropriate for this group of patients.

Kidney impairment:
In patients with kidney impairment Neomidantan® dose should be reduced or the dose interval should be increased in accordance with the creatinine clearance (see the chart).

Children below 10 years of age:
Neomidantan® is not suitable for use in children below 10 years of age due to the amount of amantadine in one capsule.


Before use, carefully read the instructions. Consult your doctor or pharmacist about the use of medicines.
Medicines unreasonable use is harmful to health.